PCWHF menopause HRT prescribing guideline
This concise summary is designed to provide support when initiating therapy, or to support in choosing alternative preparations, for the treatment of symptoms of the menopause
NICE pelvic floor dysfunction guideline
Covering the prevention, assessment, and non-surgical management of pelvic floor dysfunction in women
FSRH CHC guideline
This concise updated summary of the FSRH combined hormonal contraception guideline covers use, effectiveness, non-contraceptive benefits, and risks
RQIA planning to birth at home in Northern Ireland
A summary of guidance for maternity healthcare professionals who are providing information and supporting women in their choice of birth place
FSRH overweight, obesity, and contraception guideline
Covering evidence-based recommendations on the provision of contraception to women who are overweight or obese
Educational resources
Hormone replacement therapy (HRT): what is the role of the progestogen?
This promotional video has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0362 March 2022
Hormone replacement therapy (HRT): Overview and focus on progestogens
This promotional webinar has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0346 March 2022
Prescribing combined hormone replacement therapy (HRT) containing dydrogesterone
This promotional algorithm has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals.
View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0238 June 2021
Women of child-bearing age with inflammatory rheumatic diseases guideline
This guideline was developed by a multidisciplinary expert panel: Giles I et al with the support of an educational grant from UCB Pharma Ltd.
The importance of the progestogenic component of hormone replacement therapy in women with a uterus
Dr John Stevenson and Dr Sophia Tsiligiannis discuss progestogen prescribing in hormone replacement therapy.
Uncomplicated recurrent UTI guideline
This guideline was developed by a multidisciplinary expert panel: Rees J et al with the support of a grant from Aspire Pharma Ltd.